The White House announced 'most favored nation' (MFN) style agreements with nine major drugmakers — including Amgen, BMS, Gilead and Novartis — in an end‑of‑year policy push to align some U.S. drug prices with lower international levels. STAT reported the administration would unveil the largest batch of such pricing agreements to date, affecting Medicaid pricing for a significant share of drugs. Companies pledged to lower Medicaid prices for medicines more expensive in the U.S. than peer nations; the deals are part of a broader drug‑pricing agenda that has drawn scrutiny from industry and lawmakers. The MFN deals could reshape manufacturers’ pricing strategies, contracting practices and global launch sequencing as firms adapt to cross‑market price parity mechanisms.